Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Replimune Group, Inc. (REPL : NSDQ)

• Company Description    Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. Number of Employees: 479

• Price / Volume Information    Yesterday's Closing Price: $5.89 Daily Weekly Monthly 20 Day Moving Average: 1,986,745 shares Shares Outstanding: 82.57 (millions) Market Capitalization: $485.94 (millions) Beta: 0.74 52 Week High: $13.24 52 Week Low: $2.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.51% -25.58% 12 Week -23.67% -22.05% Year To Date -39.46% -38.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 Unicorn Park Drive Suite 303 - WOBURN,MA 01801 USA ph: 781-222-9600 fax: - ir@replimune.com http://www.replimune.com

• General Corporate Information    Officers Sushil Patel - Chief Executive Officer and Director Emily Hill - Chief Financial Officer Andrew Schwendenman - Chief Accounting Officer Philip Astley-Sparke - Director Kapil Dhingra - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76029N106 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/28/26 Share - Related Items Shares Outstanding: 82.57 Most Recent Split Date: (:1) Beta: 0.74 Market Capitalization: $485.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.46 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/28/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 2.53% vs. Previous Quarter: 14.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - -102.69 09/30/25 - -82.83 ROA 03/31/26 - - 12/31/25 - -72.22 09/30/25 - -61.62 Current Ratio 03/31/26 - - 12/31/25 - 5.60 09/30/25 - 6.31 Quick Ratio 03/31/26 - - 12/31/25 - 5.60 09/30/25 - 6.31 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 2.55 09/30/25 - 3.37 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.33 09/30/25 - 0.26 Debt-to-Capital 03/31/26 - - 12/31/25 - 24.89 09/30/25 - 20.89

Powered by Zacks Investment Research ©